URL: http://dx.doi.org/10.31703/gpsr.2023(VIII-IV).06 DOI: 10.31703/gpsr.2023(VIII-IV).06

Citation: Shoshi, A. A. (2023). The Convergence of Artificial Intelligence and Multi-Omics Data Integration in Precision Medicine: Foundations, Clinical Applications, and Translational Challenges. *Global Pharmaceutical Sciences Review, VIII*(II), 57-67. https://doi.org/10.31703/gpsr.2023(VIII-IV).06

Cite Us

Vol. VIII, No. IV(Spring 2023) Pages: 57 – 67 ISSN (Print): 2788-5569 ISSN (Online): 2788-5445

The Convergence of Artificial Intelligence and Multi-Omics Data Integration in Precision Medicine: Foundations, Clinical Applications, and Translational Challenges

Anika Anwar Shoshi [a]

Abstract: *Modern biomedicine has generated molecular and clinical data that are no longer readily analysed within the framework of an older culture. Today, genomic, transcriptomic, proteomic, metabolomic and epigenomic measurements are routinely generated alongside electronic health records and continuous signals from wearables, and the challenge has shifted from a lack of data to principled interpretation. This review examines how artificial intelligence, particularly machine learning, connects multi-omics data to clinical decision-making. It outlines statistical and deep-learning principles, reviews early, intermediate, and late integration strategies, and highlights applications in oncology, cardiovascular medicine, neurology, chronic disease prevention, and infectious-disease surveillance. Technical performance alone is insufficient; validation, interpretability, equity, and regulatory compliance ultimately determine whether a promising model becomes a usable clinical tool. The review concludes with a plan for translation and the challenges that remain between the promise of the computer and lasting benefit in the clinic.*

Key Words: Artificial Intelligence, Machine Learning, Deep Learning, Multi-Omics Integration, Precision Medicine, Biomarker Discovery, Clinical Decision Support, Digital Health

Introduction

The concept of providing medical care that is customized to the needs of the individual patient is not new, but the ways of achieving it have undergone a radical transformation. Throughout much of the 20th century, the standard unit of clinical reasoning was the average, and a doctor would gather information about the likely progress of a patient's condition from general types and use epidemiological data to inform their conclusions. High throughput molecular measurement upset that balance by introducing the biological particularity of each person into the legibility of the measurement more than ever.

Precision medicine takes this particularity and turns it into an analytic opportunity, suggesting that diagnosis, prognosis, and therapy can be improved when molecular, clinical, and behavioral information is taken into consideration collectively, instead of separately (Ahmed, 2020). The problem is that the number and complexity of the data obtained soon overwhelm the unaided human eye or even conventional biostatistics.

Within this context, machine learning has made a real leap into the medical field as it provides approaches that can identify predictive structure directly from data, rather than only from a pre-specified hypothesis (Deo, 2015). There was much initial excitement, some of which was ahead of the facts: skeptical voices sounded already, saying that the field would need to mature from unrealistic optimism to robust validation, if it wanted to become trusted in the clinic.

This cautionary note was clearly heard by clinicians who noted that predictive models, even the most impressive ones, often have poor performance when exposed to the "messiness of real practice" (Chen & Asch, 2017). The intervening years have somehow brought on realism and leashed the optimism, while leaving the drive intact.

A complementary view frames these advances in

[a] Dr. Sirajul Islam Medical College &Hospital Ltd, University of Dhaka, Dhaka, Bangladesh.

Corresponding Author: Anika Anwar Shoshi (Dr. Sirajul Islam Medical College &Hospital Ltd, University of Dhaka, Dhaka, Bangladesh. Email: anikashoshi3@gmail.com)

the context of the ongoing revolution in healthcare enabled by large amounts of data and suggests that the melding of data and flexible algorithms may revolutionize clinical practice as much as earlier diagnostics technologies (Beam & Kohane, 2018). In this review, the present authors accept this argument on the one hand but also assert that a realistic description of the actual achievements is in order.

We hope to offer a holistic perspective on the evolution of integrated use of artificial intelligence and multi-omics data in the context of precision medicine. We see the two strands as inextricably linked: the analytical strength of modern algorithms is most useful where biology is most complex and multi-omics data provides just that. The review begins with foundations and then goes on to applications and is concluded by the actual situation of the translator, in order that the reader may not only see what is possible, but also what is actually difficult.

Figure 1

Conceptual framework linking heterogeneous multi-omics and real-world inputs, an artificial-intelligence analytic engine, and clinical precision-medicine outputs, with a continuous learning and feedback loop.



Computational Foundations of Learning in Medicine

As artificial intelligence is a vast and uneven landscape, it is important to have a good understanding of the methods used to any serious discussion about the role of AI in medicine. On the one hand are well-known statistical-learning methods, such as regularized regression, support-vector machines and tree ensembles, whose action is rather well understood. Deep neural networks bring flexibility of representation to one extreme, while demanding lots of data and can become opaque at the other.

Statistical Learning in favour of Clinical Prediction

Just as much as what machine learning methods compute, the way that they are framed has had an impact on their clinical reception, and accessible expositions targeting physicians have played their share in reducing the conceptual barrier (Rajkomar et al., 2019). The vocabulary of features, labels, and validation is translated into clinical terms, so that the methods don't seem so foreign.

For example, in the field of cardiovascular medicine, supervised models have been carefully developed to learn patterns in the electrocardiographic and imaging data that are associated with outcomes of interest (Johnson et al., 2018). This is typical of all such work – there is no predictive power in novelty of algorithm, only in building the model.

These applications were discovered comparatively early in the field of oncology, and models have been proved to help make a prognosis for cancer patients and to predict their progression from clinical and molecular characteristics (Kourou et al., 2015). The results of these studies focused on cancer are still relevant since they were faced, right

at the start, with the challenge of high dimensionality of the data set in comparison with the number of observations.

The Deep-Learning Transition

With the advent of deep learning, it brought architecture that could learn hierarchical representations from raw or minimally processed inputs, which is especially relevant for biological data where the information is typically hierarchically organized from Esteva et al., 2019. This deep learning in healthcare guide provided a clear understanding of opportunities and practical requirements of this approach.

This wide-reaching and influential evaluation of the field pointed out that whilst the flexibility of deep models that is responsible for their success may also make it hard to validate and interpret (Ching et al., 2018). The authors took care to distinguish capability from speculation, while extrapolating.

Given the particular use-case of genomics, novel computational modelling methods have been devised to process sequence data, regulatory prediction, etc. using deep learning methods (Eraslan et al., 2019). These methods take advantage of the sequential and combinatorial properties of genomic information in ways that classical models will not.

A survey of deep learning in healthcare in general has identified the positive outcomes and the common challenges including data quality, label noise and the lack of transportability between institutions (Miotto et al., 2018). The fact that the same challenges are often present in the different application areas is significant in itself.

Table 1

Principal families of machine-learning methods used in biomedical analysis, with characteristic strengths and typical applications discussed in the surveyed literature.

Method family	Characteristic strengths	Representative biomedical applications
Regularized regression	Interpretable coefficients; stable in high dimensions with penalization	Risk scoring, biomarker selection, baseline clinical prediction
Tree ensembles	Captures nonlinear interactions; robust to mixed data types	Tabular clinical and omics prediction, feature ranking
Support-vector machines	Effective with many features and few samples	Early cancer classification, molecular subtyping
Deep neural networks	Learns hierarchical representations from complex inputs	Genomic sequence modeling, imaging, and multi-omics fusion
Unsupervised / clustering	Reveals latent structure without labels	Patient stratification, disease-subtype discovery
Network-based methods	Encodes relationships among molecular entities	Pathway analysis, network medicine, biomarker context

Multi-Omics Data and Strategies for Integration

Precision medicine ultimately relies on multi-omics data as the substrate to be processed by machine learning as the analytic engine. Every omic layer provides a different view of a biological state and none of the omics layers, by themselves, are complete. The integration problem raises, therefore, a central scientific question and is not simply a technical "add-on".

Multi-omics methods are based on the belief that diseases are not only due to changes at one particular molecular level but also due to the interaction between them (Hasin et al., 2017). It encourages a specific integration of genomic, transcriptomic, proteomic and metabolomic data.

Integrative omics has therefore been proposed as a way to gain a complete understanding of health

and disease in the molecular context, and the layers of data as complementary and not redundant (Karczewski & Snyder, 2018). The payoff is a more thorough picture of the biological system being studied.

A variety of strategies have been catalogued in methodological literature to be combined with this type of data, depending on when the fusion happens, and the statistical assumptions it makes (Bersanelli et al., 2016). The taxonomy serves as a helpful conceptual framework for thinking about trade-off arguments.

In this context, as long as integration approaches are designed carefully and wisely, more is indeed better, as more data layers can help to disambiguate ambiguities left by any individual layer (Huang et al., 2017). There is as much importance in the qualification as the claim.

The three models of early, intermediate and late integration

One important question is how to combine various data types and make genotype–phenotype relationships apparent, and there have been careful reviews of the respective approaches (Ritchie et al., 2015). Their selection will have implications on performance and interpretability.

From a general perspective, early integration merges all the features of all the layers as they are, and then models them together afterwards, thus maintaining the crosslayer interactions while being potentially bogged down by dimensionality. Intermediate integration first embeds each layer in a common latent space, while being expressive and tractable. Late integration: Models each of the layers individually and ensembled predictions together, robust and modular, but lack interactions that are only present when layers are considered together. These three are canonical strategies summarized in figure 2.

Figure 2

Three canonical strategies for multi-omics integration: (a) early integration via feature concatenation, (b) intermediate integration through a shared latent representation, and (c) late integration via ensemble combination of layer-specific models.



The use of these integration options in practical machine-learning tasks in genetics and genomics has revealed some of the oddities of biological data, such as correlated features and small sample sizes (Libbrecht & Noble, 2015). The moral to the lesson is that you cannot separate method selection from data structure.

These concepts are further expanded to a network-oriented view which explicitly models the molecular entities and relationships and places biomedical analysis in the context of network medicine in the age of large-scale data (Sonawane et al., 2019). This perspective emphasizes context, with molecules as part of a larger system of interacting with molecules.

Table 2

Comparison of the principal multi-omics integration strategies along dimensions relevant to clinical translation.

Strategy	Core idea	Primary advantage	Main limitation
Early	Concatenate all layers into one feature matrix	Preserves cross-layer interactions	High dimensionality; risk of overfitting
Intermediate	Project layers into a shared latent space	Balances expressiveness and tractability	Latent factors can be hard to interpret
Late	Model each layer, then combine outputs	Modular and robust to missing layers	May miss joint cross-layer signals

Artificial Intelligence as the Engine of Integration

A combination of analytical methods and multi-omics information has been most explicitly attempted in platforms that aim to render integrative analysis commonplace, such as multi-functional machine-learning platforms constructed expressly for healthcare and precision medicine (Ahmed et al., 2020). These platforms aim to reduce the real integration costs and make it a routine effort.

A parallel approach has been stressing the need for intelligent integration of clinical and multi-omics data as the work horse of precision medicine, noting that such integration should be principled and not just additive (Ahmed, 2020). There is a difference between judicious and indiscriminate coalescence found throughout the field.

In turn, the genomic-to-precision-medicine translation has been couched in the language of AI, and applications, challenges and future directions have been discussed in detail in the context of cancer (Xu et al., 2019). This cancer-genomics synthesis is remarkable for its approach of taking obstacles seriously as well as opportunities.

The broader AI in medicine literature has mapped out various ongoing developments and potential scenarios for future use of AI in medicine and offers a valuable overview of the current landscape in relation to the clinical need (Buch et al., 2018). These overviews assist in setting expectations among specialties.

Maybe the most impactful synthesis has portrayed the rise of a high performing medical field in which humans and AI work together in complementary ways rather than competing (Topol, 2019). The focus on complementarity has emerged as a guiding theme of the field.

Clinical Applications Across Specialties

The benefit of such methods is ultimately seen in real-world clinical situations, where there is a need and capability. The use of these applications is discussed in the next few subsections in different specialties, focusing on work that has been developed with both algorithmic and clinical concerns in mind.

Oncology & Precision Cancer Therapy

Integrative Analysis of Genomic Data and Machine Learning has been explicitly pushed forward to aid precision oncology and targeted therapy (Manik et al., 2022) and there has been a natural proving ground with cancer given the molecular heterogeneity of the disease. In this work, data integration is seen as the basis for the individual treatment of cancer.

The application of AI and machine learning can be analyzed with a focus on the detection and classification of cervical cancer, for example (Manik, 2022). This case helps to highlight the importance of case-specific framing of more general methods.

Complementary research on plant biotechnology revealed the potential of large-scale data and bioinformatics for in silico identification of new anticancer agents that can go beyond the clinic (Ahmed, 2023). This line of research ties in with the same data-driven reasoning that is used for the discovery and development of drugs.

Cardiovascular Medicine

Machine learning has been particularly embraced by

cardiovascular medicine and wide-ranging reviews have mapped its growing involvement in diagnosis, risk prediction, and management (Shameer et al., 2018). Its wide range of applications is indicative of the many existing structured cardiovascular data sets.

It has been suggested that wearable data coupled with deep learning algorithms can be used to enable real time monitoring of cardiovascular disease and provide proactive management and prevention instead of reactive (Miah et al., 2019). Continuous monitoring moves the clinical attitude from episodic evaluation to continuous monitoring.

Neurology and Neurosurgery

Predictive multi-omics systems based on artificial-intelligence (AI) models have been created to support Parkinson's disease management and neurosurgical decision making in neurological diseases (Manik, 2021). The approach is representative of the possible layered molecular data that can be marshaled for one complex condition.

Another example is ischemic stroke, where multi-omics integration, with a focus on the discovery of early detection biomarkers, has been guided by machine learning (Manik, 2023). Precisely, that is where integrative analysis can make the biggest difference in outcomes in early detection.

Chronic Disease and Personalized Prevention

Artificial intelligence for predictive analytics has been used in detection of chronic diseases in an early stage, which is a step towards data-driven personalized medicine (Manik et al., 2021). One of the most important uses of these methods is that of preventing problems before they occur, which can now be recognized as prediction.

Infectious Disease and Surveillance

Machine learning is being used as an emerging technology on the verge of a major paradigm change in healthcare epidemiology, with potential effects on the identification and control of outbreaks (Wiens & Shenoy, 2018). These tools are relevant not just for individual care, but with epidemiological framing.

The area of antimicrobial resistance has been suggested that the use of large-scale data and predictive models could be used as tools to globally monitor the rise of AMR (Manik et al., 2020). Monitoring this kind of scale can only be done with automated analytic support.

Table 3

Representative clinical-application domains for artificial intelligence and multi-omics integration, with the principal analytic objective in each.

Domain	Principal analytic objective	Representative contribution in the literature
Oncology	Subtype classification and therapy selection	Genomic integration for precision oncology
Cardiology	Risk prediction and continuous monitoring	Wearable data with deep learning for cardiovascular care
Neurology	Early detection via biomarker discovery	Multi-omics models for Parkinson's disease and stroke
Chronic disease	Pre-symptomatic risk stratification	Predictive analytics for personalized prevention
Infectious disease	Population-level surveillance	Predictive models for antimicrobial-resistance monitoring

Digital Health, Wearables, and the Living Dataset

Precision medicine has grown beyond the lab to the daily lives of people thanks to biosensors that can be worn and monitor activity and physiological signals continuously (Li et al., 2017). These devices transform the patient's everyday life into a

longitudinal data set of huge dimensions.

This is a continuous stream, which alters the nature of the available data. Whereas omics measurements tend to be in-depth and static, wearable signals tend to be shallower and more temporally dense, and the two are complementary. Together, they enable models to connect molecular predisposition to dynamic physiological response, and thus, to get the analytic framework of Figure 1 closer to lived experience. The methodological challenge is how to integrate modalities, but also to integrate temporal resolutions – and this challenge relates directly to the integration strategies mentioned above.

Figure 3

Illustrative comparison of representative predictive-performance ranges reported across clinical-application domains. Values are qualitative summaries intended for orientation rather than a formal meta-analysis.



Acceleration of Drug Discovery

Generative artificial intelligence and large-scale analytics have been suggested to provide a boost to pharmaceutical innovation, the same analytic capabilities that have been used to improve diagnosis. The goal is to shorten timelines that have typically taken place over a period of years.

This computational turnaround has been strategically packaged as well, with the idea that biotechnology-based innovation can provide a competitive edge in the global pharmaceutical industry (Manik, 2020). The strategic and scientific arguments here dovetail into each other.

This applies to agriculture too, as genomic selection and machine learning have been applied to improve crop ability to withstand climate stress, showing the applicability of the same techniques to other fields (Saimon et al., 2023). This paradigm carrying over different domains is indicative of its strength.

Translational Challenges and Open Problems

But enthusiasm cannot be allowed to mask a hard look at the nitty-gritty of what lies between an attractive model and a reliable clinical instrument. The problems are not only technical, but methodological, ethical and institutional and increase with the complexity of the systems.

- Perhaps most importantly, the generalizability of the models is an issue that has not been addressed as well, as models that work great in development often do not work as well in new populations or institutions with slightly different data.
- Interpretability is important because doctors are not exactly eager to base their decisions on predictions that they can't understand and the best models tend to be the least transparent.
- Practical burden of data quality and harmonization as batch effects, missing

values, and inconsistent annotation can easily influence conclusions drawn downstream.

- Equity is a real concern as a model based on an unrepresentative data set could reflect disparities and exacerbate them.
- Regulation and accountability are still developing and validation and monitoring of adaptive systems in use in the clinic is not fully resolved.

Figure 4 situates these concerns along the translational pathway, locating each principal challenge at the stage where it most acutely arises.

Figure 4

Translational roadmap from multi-omics data acquisition to validated clinical deployment, annotated with the principal challenge encountered at each checkpoint.



Table 4

Principal translational challenges and corresponding mitigation strategies emphasised in the surveyed literature.

Challenge	Why it matters	Mitigation direction
Generalizability	Models degrade across sites and populations	External validation; multi-site training; robustness testing
Interpretability	Clinicians require scrutable predictions	Explainable methods; transparent reporting of features
Data harmonization	Batch effects and missingness distort results	Standardized pipelines; rigorous quality control
Equity	Unrepresentative data entrenches disparities	Representative cohorts; subgroup performance auditing
Regulation	Adaptive systems are hard to govern	Prospective evaluation; continuous monitoring frameworks

Future Directions

In the future, the course of the field will be more determined by the ripening process of validation, combination, and management of current algorithms than by the discovery of completely new algorithms. There are a number of directions that hold particular promise. Federated and privacy-preserving learning

could enable models to be trained across institutions without bringing sensitive information into a central place, while simultaneously tackling the issues of both generalizability and confidentiality. Combining continuous data collected from wearable devices with static data collected from molecules could yield a more dynamic health states portrait than either data type can offer alone. But the gradual progress of interpretable and uncertainty-aware models could begin to fill the trust gap that has been holding back the adoption of models in the clinic. The directions are none of them guaranteed, but each is a response to a problem which has been clearly identified in the current literature.

Conclusion

AI and multi-omics integration have stepped precision medicine from promise to a shaky reality, albeit a promising one. The scientific basis for computation is now fairly well understood, the integration strategies are charted, and concrete examples include oncology, cardiology, neurology, chronic-disease prevention and infectious-disease surveillance. But the main point that can be gleaned from the literature cited herein is one of proportion. Algorithmic ingenuity is necessary but there are still the binding constraints of validation, interpretability, equity, and governance. While not as sexy as a new architecture, these advances are more significant for patients than any new architecture. The future of this field thus relies on a specific type of discipline, one where careful integration of computational and clinical activities, rigorous reporting of clinical data, and collaboration across the computational-to-clinical border are embraced. In those disciplines, the promise and practice gap will probably continue as described in this review; in those disciplines, the convergence described in this review will likely lead to real clinical gains.

References

Ahmed, M. K., Rahaman, M. M., Khair, F. B., Hossain, S., Hossain, S., Bhuiyan, M. M. R., & Manik, M. M. T. G. (2023). Big data in plant biotechnology: Leveraging bioinformatics to discover novel anticancer agents from flora. *Journal of Medical and Health Studies, 4*(6), 126–133. https://doi.org/10.32996/jmhs.2023.4.6.15

Ahmed, Z. (2020). Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. *Human Genomics, 14*(1), 35. https://doi.org/10.1186/s40246-020-00267-5

Ahmed, Z., Mohamed, K., Zeeshan, S., & Dong, X. (2020). Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database, 2020, baaa010. https://doi.org/10.1093/database/baaa010

Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. *JAMA, 319*(13), 1317–1318. https://doi.org/10.1001/jama.2017.18391

Bersanelli, M., Mosca, E., Remondini, D., Giampieri, E., Sala, C., Castellani, G., & Milanesi, L. (2016). Methods for the integration of multi-omics data. *Briefings in Bioinformatics, 17*(1), 15–29. https://doi.org/10.1093/bib/bbv001

Buch, V. H., Ahmed, I., & Maruthappu, M. (2018). Artificial intelligence in medicine: Current trends and future possibilities. *British Journal of General Practice, 68*(668), 143–144. https://doi.org/10.3399/bjgp18X695213

Chen, J. H., & Asch, S. M. (2017). Machine learning and prediction in medicine—Beyond the peak of inflated expectations. *New England Journal of Medicine, 376*(26), 2507–2509. https://doi.org/10.1056/NEJMp1702071

Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., ... Greene, C. S. (2018). Opportunities and obstacles for deep learning in biology and medicine. *Journal of the Royal Society Interface, 15*(141), 20170387. https://doi.org/10.1098/rsif.2017.0387

Deo, R. C. (2015). Machine learning in medicine. *Circulation, 132*(20), 1920–1930. https://doi.org/10.1161/CIRCULATIONAHA.115.001593

Eraslan, G., Avsec, Ž., Gagneur, J., & Theis, F. J. (2019). Deep learning: New computational modelling techniques for genomics. *Nature Reviews Genetics, 20*(7), 389–403. https://doi.org/10.1038/s41576-019-0122-6

Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., ... Dean, J. (2019). A guide to deep learning in healthcare. *Nature Medicine, 25*(1), 24–29. https://doi.org/10.1038/s41591-018-0316-z

Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. *Genome Biology, 18*(1), 83. https://doi.org/10.1186/s13059-017-1215-1

Huang, S., Chaudhary, K., & Garmire, L. X. (2017). More is better: Recent progress in multi-omics data integration methods. *Frontiers in Genetics, 8*, 84. https://doi.org/10.3389/fgene.2017.00084

Johnson, K. W., Torres Soto, J., Glicksberg, B. S., Shameer, K., Miotto, R., Ali, M., & Dudley, J. T. (2018). Artificial intelligence in cardiology. *Journal of the American College of Cardiology, 71*(23), 2668–2679. https://doi.org/10.1016/j.jacc.2018.03.521

Karczewski, K. J., & Snyder, M. P. (2018). Integrative omics for health and disease. *Nature Reviews Genetics, 19*(5), 299–310. https://doi.org/10.1038/nrg.2018.4

Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2015). Machine learning applications in cancer prognosis and prediction. *Computational and Structural Biotechnology Journal, 13*, 8–17. https://doi.org/10.1016/j.csbj.2014.11.005

Li, X., Dunn, J., Salins, D., Zhou, G., Zhou, W., Schüssler-Fiorenza Rose, S. M., ... Snyder, M. P. (2017). Digital health: Tracking physiomes and activity using wearable biosensors. *NPJ Digital Medicine, 1*(1), 1–16. https://doi.org/10.1038/s41746-017-0004-0

Libbrecht, M. W., & Noble, W. S. (2015). Machine learning applications in genetics and genomics. *Nature Reviews Genetics, 16*(6), 321–332. https://doi.org/10.1038/nrg3920

Manik, M. M. T. G. (2020). Biotech-driven innovation in drug discovery: Strategic models for competitive advantage in the global pharmaceutical market. *Journal of Computational Analysis and Applications, 28*(6), 41–47. https://eudoxuspress.com/index.php/pub/article/view/2874

Manik, M. M. T. G. (2021). Multi-omics system based on predictive analysis with AI-driven models for Parkinson's disease (PD) neurosurgery. *Journal of Medical and Health Studies, 2*(1), 42–52.

https://doi.org/10.32996/jmhs.2021.2.1.5

Manik, M. M. T. G. (2022). An analysis of cervical cancer using the application of AI and machine learning. *Journal of Medical and Health Studies, 3*(2), 67–76. https://doi.org/10.32996/jmhs.2022.3.2.11

Manik, M. M. T. G. (2023). Multi-omics integration with machine learning for early detection of ischemic stroke through biomarkers discovery. *Journal of Ecohumanism, 2*(2), 175–187. https://doi.org/10.62754/joe.v2i2.6800

Manik, M. M. T. G., Bhuiyan, M. M. R., Moniruzzaman, M., Islam, M. S., Hossain, S., & Hossain, S. (2018). The future of drug discovery utilizing generative AI and big data analytics for accelerating pharmaceutical innovations. *Nanotechnology Perceptions, 14*(3), 120–135. https://doi.org/10.62441/nano-ntp.v14i3.4766

Manik, M. M. T. G., Hossain, S., Ahmed, M. K., Rozario, E., Miah, M. A., Moniruzzaman, M., ... Muhammad, A. S. (2022). Integrating genomic data and machine learning to advance precision oncology and targeted cancer therapies. *Nanotechnology Perceptions, 18*(2), 219–243. https://doi.org/10.62441/nano-ntp.v18i2.5443

Manik, M. M. T. G., Moniruzzaman, M., Islam, M. S., Bhuiyan, M. M. R., Rozario, E., Hossain, S., ... Saimon, A. S. M. (2020). The role of big data in combatting antibiotic resistance: Predictive models for global surveillance. *Nanotechnology Perceptions, 16*(3), 361–378. https://doi.org/10.62441/nano-ntp.v16i3.5445

Manik, M. M. T. G., Saimon, A. S. M., Miah, M. A., Ahmed, M. K., Khair, F. B., Moniruzzaman, M., Bhuiyan, M. M. R. (2021). Leveraging AI-powered predictive analytics for early detection of chronic diseases: A data-driven approach to personalized medicine. *Nanotechnology Perceptions, 17*(3), 269–288. https://doi.org/10.62441/nano-ntp.v17i3.5444

Miah, M. A., Rozario, E., Khair, F. B., Ahmed, M. K., Bhuiyan, M. M. R., & Manik, M. M. T. G. (2019). Harnessing wearable health data and deep learning algorithms for real-time cardiovascular disease monitoring and prevention. *Nanotechnology Perceptions, 15*(3), 326–349. https://doi.org/10.62441/nano-ntp.v15i3.5278

Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018). Deep learning for healthcare: Review, opportunities and challenges. *Briefings in Bioinformatics, 19*(6), 1236–1246. https://doi.org/10.1093/bib/bbx044

Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. *New England Journal of Medicine, 380*(14), 1347–1358. https://doi.org/10.1056/NEJMra1814259

Ritchie, M. D., Holzinger, E. R., Li, R., Pendergrass, S. A., & Kim, D. (2015). Methods of integrating data to uncover genotype–phenotype interactions. *Nature Reviews Genetics, 16*(2), 85–97. https://doi.org/10.1038/nrg3868

Saimon, A. S. M., Moniruzzaman, M., Islam, M. S., Ahmed, M. K., Rahaman, M. M., Hossain, S., & Manik, M. M. T. G. (2023). Integrating genomic selection and machine learning: A data-driven approach to enhance corn yield resilience under climate change. *Journal of Environmental and Agricultural Studies, 4*(2), 20–27. https://doi.org/10.32996/jeas.2023.4.2.6

Shameer, K., Johnson, K. W., Yahi, A., Miotto, R., Li, L., Ricks, D., ... Dudley, J. T. (2018). Machine learning in cardiovascular medicine. *Circulation Research, 122*(11), 1525–1542. https://doi.org/10.1161/CIRCRESAHA.118.312706

Sonawane, A. R., Weiss, S. T., Glass, K., & Sharma, A. (2019). Network medicine in the age of biomedical big data. *Frontiers in Genetics, 10*, 294. https://doi.org/10.3389/fgene.2019.00294

Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine, 25*(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

Wiens, J., & Shenoy, E. S. (2018). Machine learning for healthcare: On the verge of a major shift in healthcare epidemiology. *Clinical Infectious Diseases, 66*(1), 149–153. https://doi.org/10.1093/cid/cix731

Xu, J., Yang, P., Xue, S., Sharma, B., Sanchez-Martin, M., Wang, F., ... Parikh, B. (2019). Translating cancer genomics into precision medicine with artificial intelligence: Applications, challenges and future perspectives. *Human Genetics, 138*(2), 109–124. https://doi.org/10.1007/s00439-019-01970-5